© Getty Images

AbbVie receives greenlight from NICE for blood cancer treatment

By Isabel Cameron

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (tepkinly), its treatment for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing blood cancer, whose cancer...

Getty Images ©

AbbVie feels biosimilar impact on Humira sales

By Ben Hargreaves

In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.

© GettyImages/Mikhail Makarov

Biosimilars organization hails US legislative effort

By Jane Byrne

The Biosimilars Forum has welcomed a move by US congressman, Richard Hudson, to introduce legislation that would establish a shared savings reimbursement model for biosimilars in Medicare Part B.

© GettyImages/ardaguldogan

FDA reviewing higher dose Hyrimoz biosimilar

By Jane Byrne

The US FDA has accepted a supplemental biologics license application (sBLA) from Sandoz for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar, Hyrimoz.

© GettyImages/Olivier Le Moal

Amneal secures second US biosimilars approval

By Jane Byrne

Last week saw the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product.